University of California San Francisco, San Francisco, CA.
Citations 1
Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for
BRCA1/2
or
PALB2
Mutant Metastatic Pancreatic Du
JCO Oncology Advances | October 31, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available